UBS (Lux) Equity Fund - Biotech (USD) P-acc
UBS (Lux) Equity Fund (FCP domiciled in Luxembourg)
Key Information
Legal Documents
Performance
Analysis

Fund Profile

Category: FCP

The fund primarily invests globally in equities of companies with a connection to the biotechnology sector. Working on the basis of well-grounded analyses by our investment specialists worldwide, the fund manager combines carefully selected equities of various companies from various countries and segments with the objective of exploiting interesting earnings opportunities while keeping the level of risk under control. In principle, investors may ask the Management Company to redeem their units on any business day in Luxembourg. Income of this share class is reinvested.

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Risk and reward profile
7
Lower Risk
Possible Lower
Returns
Higher Risk
Possible Higher
Returns
Key Information
Closing Price 22/05/2020732.31
Morningstar categorySector Equity Biotechnology
CurrencyUSD
Distribution statusAccumulating
ISINLU0069152568
Inception Date15/10/1996
Minimum initial amount100.00 USD
Fees And Charges
Entry feeNone
Custody feeNone
Exit feeNone
Ongoing charge2.10% of which 0.82% is paid to MeDirect
Fund management company
AddressUBS Fund Management (Luxembourg) S.A. 33A, avenue J.-F. Kennedy, L-1855 Luxembourg Luxembourg L-1855 Luxembourg
Manager NameNathalie Lötscher Petrus
Manager Start Date30/11/2006
Websitewww.ubs.com/funds
Total Net Assets (mil)1,033.77 USD (30/04/2020)
UCITSYes
AdministratorNorthern Trust Global Services SE

Documents

Prospectus
en 01/06/2019
Annual Report
en 30/11/2019
Semi Annual Report
en 31/05/2019
Morningstar Report
26/05/2020

Performance

Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
The performance in euro can be lower or higher than the performance in the currency of denomination of the fund due to fluctuations in exchange rates.
Annualised performance in USD
PeriodAnnualised returnDate
1 year28.90%22/05/2020
3 years10.98%22/05/2020
5 years2.24%22/05/2020
10 years16.10%22/05/2020
Since launch8.80%22/05/2020
Cumulative performance in USD
Performance
YTD 01/01/202011.69
1 month8.52
3 months6.93
6 months17.40
Quarterly Returns
Q 1Q 2Q 3Q 4
2020-10.39%---
201916.73%-2.36%-9.66%22.62%
2018-2.95%4.42%5.31%-17.59%
201714.24%7.31%8.42%-5.62%
2016-21.50%0.83%13.33%-7.56%
Dividend
No Data Available

Asset Allocation
% Long% Short% Net Assets
Stock99.55%0.00%99.55%
Bond0.00%0.00%0.00%
Cash0.68%0.23%0.45%
Other0.00%0.00%0.00%
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
25.2722.7624.89
Sharpe Ratio
0.700.330.17
Sortino Ratio
1.550.540.24
Positive Months6.0018.0031.00
Negative Months6.0018.0029.00
Worst Month-6.99-13.55-21.18
World Regions
Region%
United States85.76
Europe - ex Euro6.63
Eurozone4.05
United Kingdom3.12
Stock Sector Weighting
Sector% of Equity
Healthcare99.55
Top 10 Holdings
HoldingSectorCountry% of Assets
Vertex Pharmaceuticals Inc HealthcareUnited States9.63
Biomarin Pharmaceutical Inc HealthcareUnited States6.23
AbbVie Inc HealthcareUnited States6.23
Gilead Sciences Inc HealthcareUnited States6.05
Incyte Corp HealthcareUnited States5.79
Seattle Genetics Inc HealthcareUnited States5.25
Alnylam Pharmaceuticals Inc HealthcareUnited States4.61
Amgen Inc HealthcareUnited States4.29
Biogen Inc HealthcareUnited States3.93
Genmab A/S HealthcareDenmark3.44
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Large
Size
Mid
Small
Value
Blend
Growth
Style
$
732.31
Closing Price
All key information and documents must be reviewed before being able to Invest.